Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN, OTCQB:KHRNF, Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that Sidney Himmel has resigned as Director and Chair of the Board to pursue other interests, effective immediately.

“On behalf of my fellow directors, the Company’s management team, and shareholders we thank Sid for his many contributions to Khiron since its founding,” said Alvaro Torres, Khiron’s CEO and Director. “Drawing on a wealth of experience over a long and successful business career, Sid helped Khiron grow in just three years from formation into one of the leading cannabis companies in Latin America. We are grateful for his contributions and wish him all the best going forward.”


Khiron’s Board of Directors has appointed CEO Alvaro Torres as Interim Board Chair until a new independent director is appointed to fill the vacancy created by Mr. Himmel’s resignation.  In addition, Khiron’s Board of Directors has appointed Deborah Rosati, FCPA, FCA, ICD.D, to replace Mr. Himmel as Chair of the Audit Committee.  As previously noted in the announcement of Ms. Rosati’s appointment to the Board of Directors of Khiron on November 4, 2019, Ms. Rosati brings a wealth of audit experience including positions as Vice Chair & Chair of the Audit Committee at cannabis authority Lift & Co (TSXV: LIFT), past Chair of the Audit Committee at Sears Canada Inc., a Member of the Department Audit Committee at Correction Services Canada, and at NexJ Systems Inc. where she was a Board member and Chair of the Audit Committee.

About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company delivers best in class regulatory compliance, has the first approved set of CBD cosmetic products on shelf in Colombia, and is currently facilitating testing to meet and surpass all license requirements for commercial cannabis derived products.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Cautionary Notes

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN, OTC:KHRNF) for an Investor Presentation.

Source

NYSE | TSX: ACB

Aurora Cannabis Inc. (“Aurora” or the “Company”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital Markets and ATB Capital Markets, under which the underwriters have agreed to buy on bought deal basis 12,000,000 units of the Company (the “Units”), at a price of US$10.45 per Unit for gross proceeds of approximately US$125 million (the “Offering”). Each Unit will be comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less